SK Capital Partners has completed its acquisition of LISI Group’s Medical division and launched the business under a new name, Precera Medical. The company has shifted its headquarters to Big Lake, Minnesota, and will operate as an independent contract development and manufacturing organization serving global medical device manufacturers. LISI Group has retained a minority ownership position as part of the deal.
Precera Medical specializes in the development and production of high-precision components and assemblies for complex medical applications. The company supports customers in surgical robotics, minimally invasive surgery, orthopedics, and interventional therapies. Its operations span four manufacturing sites, two in Minnesota and two in France, with capabilities including development, rapid prototyping, precision machining, forging, and automated production.
Alongside the formal close of the transaction, Precera Medical has strengthened its leadership team. Dylan Hushka, a veteran of the CDMO sector and most recently President of DuPont’s healthcare CDMO business, has been appointed Chief Executive Officer. Barry Lederman has joined as Chief Financial Officer following prior CFO roles at Worldwide Clinical Trials and past collaboration with SK Capital portfolio companies.
The company has also established an Advisory Board composed of senior industry executives and representatives from both SK Capital and LISI Group. The board includes Chris Qualters, Art Burghouwt, Brian Hutchison, Aaron Davenport, Josh Lieberman, and Emmanuel Viellard.
SK Capital plans to support the company’s growth through expanded capacity and enhanced capabilities, including the potential for strategic acquisitions. The firm sees a strong opportunity for Precera Medical to deepen partnerships with medical technology innovators and accelerate product development across advanced therapeutic areas.
Support: Piper Sandler, Jefferies, and Sycomore Corporate Finance served as financial advisors to SK Capital, while Rothschild & Co advised LISI Group. Legal counsel was provided by Kirkland & Ellis for SK Capital and Dentons for LISI Group. Debt financing was arranged by Partners Group and Deutsche Bank.
KEY QUOTES
“I am proud to join the Precera Medical team and, as a former customer, have been impressed by Precera’s world-class engineering, manufacturing, automation, quality assurance, and customer focus. With more than 75 years of contract development and manufacturing excellence, Precera continues to innovate and invest in enabling market-leading medical device OEMs to launch breakthrough technologies that impact millions of patients each year. This is a new era of precision manufacturing defined by speed, reliability, and uncompromising quality. I am excited to lead the team as we establish Precera Medical as a thriving, independent company and continue to be a true strategic extension of our customers’ teams to drive improved patient outcomes.”
Dylan Hushka, Chief Executive Officer, Precera Medical
“We are thrilled to be partnering with Dylan, the management team, LISI and the Board to support the Company’s next chapter as Precera Medical. We plan to support continued investment in capacity and expanded capabilities, both organically and through M&A, to support leading OEMs across the most advanced areas of medical technology and accelerate growth.”
Josh Lieberman, Principal, SK Capital
“This transaction marks the close of an important chapter for LISI Group and the beginning of an exciting one for Precera Medical. I am proud of the growth we achieved since we established the division in 2010. The long-term foundation we invested in, combined with SK Capital’s industry and financial resources, will enable Precera Medical to thrive as an independent company supporting the growth of its customers.”
Emmanuel Viellard, CEO, LISI Group
